Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

APC-004

45 evidence topics · 5 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using hypoxic burden as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed for the primary outcome in the registry
FieldQuoted record
Enrollment (actual)“Enrollment (Actual) 32”
Participants analyzed for the primary outcome, each comparison“Overall Number of Participants Analyzed 27 27 27”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Respiratory polysomnography parameters by treatment, median (interquartile range), AHI and ODI with 4% desaturation criterion
Registry primary outcome: mean difference in hypoxic burden (95% confidence interval), events with 4% or greater desaturation
ComparisonLog10 HB, difference in log10HB[(%*min)/h]Raw HB, (%*min)/h
AD109 dose 1 (atomoxetine 75 mg) vs placebo“-0.40 (-0.54 to -0.25)”“-6.90 (-10.20 to -3.60)”
AD109 dose 2 (atomoxetine 37.5 mg) vs placebo“-0.21 (-0.36 to -0.07)”“-4.70 (-8.01 to -1.38)”
Dose 2 vs dose 1“0.18 (0.04 to 0.33)”“2.20 (-1.23 to 5.36)”
Health-related quality of life and patient-reported outcomes
Safety results
Registry adverse events: deaths, serious adverse events, and other adverse events at a 5% threshold
Sleep and morning vital signs by treatment, median (interquartile range)
Study limitations
Summary
  • Design: single-dose crossover with one night of polysomnography per treatment, separated by washouts of at least 1 week.
  • Population: AHI4 of 5 to 20 events/h, ages 25 to 65, and BMI 18.5 to 40.0 kg/m2, with exclusion of other active sleep disorders, medications affecting respiratory, muscle, or neurologic function, and unstable medical disorders (the prospectus names a history of insomnia). The registry describes the population as mild obstructive sleep apnea, and the publication as mild or low-moderate OSA.
  • Size: 32 participants were randomized, 31 were treated, and 27 were analyzed for each primary comparison in the registry.
  • Hypoxic burden definition differs by source: the publication includes each apnea or hypopnea regardless of associated desaturation, and the registry includes events with 4% or greater desaturation. An accompanying editorial states that further validation of the measure is needed.
  • REM analysis: only 13 participants had REM sleep on both placebo and high-dose AD109, which the authors state left the REM analysis without statistical power.
  • Funding: the publication states the study was funded by Apnimed.